![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://www.preprints.org/frontend/picture/ms_xml/manuscript/fd91b5ed5a3d9b401eee39745144b181/preprints-172687-g004.png)
foxo4-dri senolytic peptide human trial 2024 2025
foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast
FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Buy FOXO4 DRI 10mg Third Party Tested BioEdge Peptides Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
USD22.73
USD70.73
Pay in 4 interest-free payments of $5.68 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs42003-025-07738-0/MediaObjects/42003_2025_7738_Fig1_HTML.png)
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://bioedgeresearchlabs.com/wp-content/uploads/2026/06/3D-FOXO4-DRI-10mg-scaled.png)
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/11921816/7ad68fa97b6d/j_jtim-2025-0005_fig_002.jpg)
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://pubs.acs.org/cms/10.1021/acs.jmedchem.5c00537/asset/images/medium/jm5c00537_0006.gif)
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://www.mdpi.com/diabetology/diabetology-06-00048/article_deploy/html/images/diabetology-06-00048-g002-550.jpg)
![foxo4-dri senolytic peptide human trial 2024 2025 Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4-DRI induces keloid senescent fibroblast](https://peptpedia.org/images/peptides/foxo4-dri.png)